Inspire Medical Systems’ (INSP) “Neutral” Rating Reiterated at Bank of America

Inspire Medical Systems (NYSE:INSP)‘s stock had its “neutral” rating reaffirmed by analysts at Bank of America in a report issued on Tuesday, MarketBeat reports. They presently have a $53.00 target price on the stock. Bank of America‘s target price would suggest a potential downside of 3.22% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. UBS Group set a $67.00 target price on Inspire Medical Systems in a report on Friday, February 13th. Stifel Nicolaus cut their target price on Inspire Medical Systems from $85.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, April 10th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $56.00 target price on shares of Inspire Medical Systems in a report on Tuesday, April 14th. Robert W. Baird set a $74.00 price objective on Inspire Medical Systems and gave the company a “neutral” rating in a research note on Thursday, February 12th. Finally, Wells Fargo & Company set a $70.00 price objective on Inspire Medical Systems and gave the company an “equal weight” rating in a research note on Thursday, February 12th. Four equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $95.72.

Inspire Medical Systems Stock Performance

Inspire Medical Systems stock opened at $54.77 on Tuesday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 2.92 and a beta of 0.83. Inspire Medical Systems has a 52-week low of $48.30 and a 52-week high of $163.35. The stock’s 50 day moving average price is $56.73 and its two-hundred day moving average price is $79.64.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. During the same period in the prior year, the business earned $0.10 EPS. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, equities research analysts forecast that Inspire Medical Systems will post 1.82 EPS for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Several large investors have recently made changes to their positions in the business. Principal Financial Group Inc. increased its position in shares of Inspire Medical Systems by 1.0% during the 1st quarter. Principal Financial Group Inc. now owns 126,788 shares of the company’s stock valued at $6,540,000 after purchasing an additional 1,269 shares during the last quarter. Fifth Third Bancorp increased its position in shares of Inspire Medical Systems by 1,794.4% during the 1st quarter. Fifth Third Bancorp now owns 6,441 shares of the company’s stock valued at $332,000 after purchasing an additional 6,101 shares during the last quarter. New York State Teachers Retirement System increased its position in shares of Inspire Medical Systems by 9.3% during the 1st quarter. New York State Teachers Retirement System now owns 23,599 shares of the company’s stock valued at $1,217,000 after purchasing an additional 2,004 shares during the last quarter. Y Intercept Hong Kong Ltd increased its position in shares of Inspire Medical Systems by 124.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 158,274 shares of the company’s stock valued at $8,164,000 after purchasing an additional 87,639 shares during the last quarter. Finally, Leonteq Securities AG increased its position in shares of Inspire Medical Systems by 187.3% during the 1st quarter. Leonteq Securities AG now owns 22,812 shares of the company’s stock valued at $1,177,000 after purchasing an additional 14,873 shares during the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 beat on EPS and revenue: Inspire reported $0.10 EPS (vs. expectations for a loss) and $204.6M in revenue, a modest year-over-year increase and slightly above consensus — shows underlying procedure demand held up in the quarter. Read More.
• Neutral Sentiment: Earnings call and details: Management discussed operational drivers and the timing impact of reimbursement/coding headwinds and the WISeR disruption — useful for modeling cadence but contained no offsetting near-term revenue levers. Read More.
• Negative Sentiment: Guidance cut materially lowers FY26 targets: Inspire lowered FY2026 revenue guidance to $825M–$875M and EPS to $0.75–$1.25, well below consensus — the reset is the main driver of the trader reaction and forces downward revisions to FY26 models. Read More.
• Negative Sentiment: Reimbursement/coding and WISeR disruption cited as causes: Management specifically blamed coding changes and disruption related to WISeR (workflow/servicing) for reduced procedure volumes and reimbursement uncertainty — this raises execution and policy risk until coding/reimbursement pathways normalize. Read More.
• Negative Sentiment: Market reaction and coverage: Media and market reports noted the sharp intraday pullback after guidance — highlights how the guidance reset dominated the beat and forced rapid re-pricing. Read More.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.